Glioblastoma therapeutics market to double in APAC by 2020

The market is estimated to double from $49.4 mn in 2013 to $105.8 mn by 2020


Glioblastoma multiforme is an aggressive brain tumor in humans

Glioblastoma multiforme (GBM) therapeutics market in Asia-Pacific (APAC) is estimated to grow double from USD49.4 million in 2013 to USD105.8 million by 2020, at a compound annual growth rate (CAGR) of 11.5 percent, according to market analyst GBI Research.

Glioblastoma multiforme is a common and aggressive malignant primary brain tumor in humans. The growth in therapy market is resulted from the anticipated approval and market entries of Rindopepimut, Cotara and Avastin in APAC countries in the coming years.

Mr Vijaya Vulapalli, senior analyst, GBI Research, commented, "The APAC region boasts a strong GBM pipeline, which also includes carmustine implants, currently being developed in China. Novel therapies Rindopepimut and Cotara in particular could have a significant bearing on APAC's GBM treatment landscape.

"Phase II clinical studies of Rindopepimut demonstrated a relatively high median Overall Survival (OS) rate among patients. Meanwhile, Cotara's Phase II studies showed similar OS to Avastin, with slightly more progression-free survival improvement in recurrent GBM. As a single-infusion therapy, Cotara is likely to become an effective second-line treatment option for patients."

However, GBI Research states that even if the therapies prove successful in late-stage clinical trials, they will experience low uptake in their respective markets due to their high prices and lack of patient access to medicines, mainly in China and India.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email